Molecular structure of YM-53601, CAS Number: 182959-33-7
YM-53601 (CAS 182959-33-7)
See product citations (3)
Alternate Names:
2-[(2E)-2-(1-azabicyclo[2.2.2]oct-3-ylidene)-2-fluoroethoxy]-9H-carbazole, monohydrochloride
Application:
YM-53601 is a squalene synthetase inhibitor
CAS Number:
182959-33-7
Purity:
≥98%
Molecular Weight:
372.9
Molecular Formula:
C21H21FN2O•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
YM-53601 inhibits squalene synthetase activity in rat hepatic microsomes and human HepG2 cells. YM-53601 can also inhibit cholesterol biosynthesis (ED50 = 32 mg/kg), causing a reduction in both cholesterol and triglyceride levels in plasma. The lipid-lowering properties of compounds such as YM-53601 make them interesting research opportunities for alternatives to combination HMG-CoA reductase inhibitor/fibrate therapy.
YM-53601 (CAS 182959-33-7) References
- YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. | Ugawa, T., et al. 2000. Br J Pharmacol. 131: 63-70. PMID: 10960070
- Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. | Ugawa, T., et al. 2002. Br J Pharmacol. 135: 1572-8. PMID: 11906972
- Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. | Ugawa, T., et al. 2002. Br J Pharmacol. 137: 561-9. PMID: 12359639
- YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. | Ugawa, T., et al. 2003. Br J Pharmacol. 139: 140-6. PMID: 12746232
- Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. | Ishihara, T., et al. 2003. Bioorg Med Chem. 11: 3735-45. PMID: 12901918
- Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. | Montero, J., et al. 2008. Cancer Res. 68: 5246-56. PMID: 18593925
- Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. | Fukamachi, T., et al. 2010. Cancer Lett. 297: 182-9. PMID: 20831979
- Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. | Park, EM., et al. 2014. FEBS Lett. 588: 1813-20. PMID: 24690320
- Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells. | Benakanakere, I., et al. 2014. Exp Hematol Oncol. 3: 24. PMID: 25401046
- Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus. | Saito, K., et al. 2015. J Virol. 89: 2220-32. PMID: 25473062
- Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells. | Statt, S., et al. 2015. Am J Respir Cell Mol Biol. 53: 689-702. PMID: 25874372
- Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. | Kobayashi, Y., et al. 2017. Oncotarget. 8: 72147-72156. PMID: 29069775
- Ionizing Radiation induction of cholesterol biosynthesis in Lung tissue. | Werner, E., et al. 2019. Sci Rep. 9: 12546. PMID: 31467399
- Discovery of a Small-Molecule-Dependent Photolytic Peptide. | Takemoto, Y., et al. 2020. J Am Chem Soc. 142: 1142-1146. PMID: 31899620
Inhibitor of:
CYP26B1, Squalene synthetase, and SREBP-2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
YM-53601, 500 µg | sc-205543 | 500 µg | $336.00 | |||
YM-53601, 1 mg | sc-205543A | 1 mg | $480.00 |